REVIEW

The year in cardiology 2016: acute coronary syndromes
Filippo Crea1*, Ronald K. Binder2, and Thomas F. Lüscher2
Received 19 October 2016; revised 22 November 2016; editorial decision 1 December 2016; accepted 2 January 2017

PREAMBLE

The year 2016 brought us several studies on the pathophysiology of acute coronary syndrome (ACS), in particular, on the role of basophils and eosinophils in the mechanism of disease. New puzzling data have also emerged on the pathomechanisms of very late stent thrombosis and the role of neutrophils in ventricular remodelling. New information has also been published on the early diagnosis of ACS by high sensitivity troponin (hsTn) and the role of new exciting biomarkers and clinical scores on risk stratification. With regards to antithrombotic treatment, the year 2016 has brought important new data on the duration of dual antiplatelet therapy (DAPT) and on the management of the growing population of very elderly. Finally, new interesting information has been published on the outcome of specific patient subsets. The studies reported in this review are summarized in Table 1.

MECHANISMS

Pathogenesis of ACS

Spontaneous ACS can be caused by plaque fissure, plaque erosion, or functional alterations of epicardial coronary arteries or by vasoconstriction of the microcirculation. Activation of inflammatory cells plays a key role in both plaque fissure and erosion although the mechanisms leading to plaque instability are substantially different in these two conditions. Indeed, while monocyte and lymphocyte activation is the key alteration in plaque fissure, neutrophil activation is a crucial player in plaque erosion. The role of eosinophil and basophil activation is still largely unknown. Niccoli et al.1 found a higher degree of both eosinophil and basophil activation, as assessed by flow cytometry, in patients with ACS than in those with stable angina. Furthermore, in a prospective cohort study they found that higher levels of eosinophil cationic protein (ECP) were associated with a worse outcome during follow-up. This suggests that novel therapies targeting eosinophils should be tested in ACS patients exhibiting raised ECP levels.

Stent thrombosis

It is well known that very late stent thrombosis is a possible cause of ACS. The pathomechanisms underlying very late stent thrombosis after implantation of drug-eluting stents (DES) are incompletely understood. Using optical coherence tomography (OCT), Taniwaki et al.2 investigated potential causes of this adverse event. They found that the leading associated findings in very late stent thrombosis were in descending order: (i) stent malapposition, (ii) neoatherosclerosis, (iii) uncovered stent struts, and (iv) stent underexpansion. The longitudinal extension of malapposed and uncovered struts was the most important correlate of thrombus formation. These findings might further expand the clinical utilization of OCT in optimizing the results of stent implantation.

Remodelling

Another important issue in ACS are the mechanisms responsible for left ventricular remodelling after myocardial infarction (MI). In an elegant experimental study in a mice model of MI, Horckmans et al.3 found that neutrophil-depleted animals had worsened cardiac function, increased fibrosis, and progressively developed...
While high neutrophil counts are considered predictors of adverse clinical outcomes and mortality in patients with ACS, these data suggest that neutrophils participate in MI repair skewing macrophages towards a resolving phenotype, which mediates efficient clearance of cell debris. This novel role for neutrophils should be taken into account when designing and applying ‘aggressive’ anti-neutrophil treatments in the setting of MI.

**EARLY DIAGNOSIS**

**Troponins**

The evaluation of patients presenting at the emergency department (ED) with suspected ACS remains a clinical challenge. The traditional assessment includes clinical risk assessment based on symptoms, cardiovascular (CV) risk factors with serial electrocardiograms and hsTn measurements, often followed by advanced cardiac testing as inpatients or outpatients. With regards to hsTn, several cohort studies have shown that patients with undetectable plasma hsTn concentrations at presentation are at low risk of MI. However, the
Filippo Crea et al.
The year in cardiology 2016: acute coronary syndromes

Figure 1. Kaplan–Meier estimated event rates of non-coronary artery bypass grafting-related major bleeding (top panel) and cardiovascular death (bottom panel) by quartiles of growth differentiation factor-15 (ng/L) assessed in 16 876 patients admitted with acute coronary syndrome. CABG, coronary artery bypass grafting; CV, cardiovascular. Reproduced with permission from Hagstrom et al.11

optimal approach and threshold of hsTn for the identification of low-risk patients suitable for immediate discharge is still debated. Shah et al.4 did a prospective cohort study of 6304 consecutively enrolled patients with suspected ACS presenting to 4 secondary and tertiary care hospitals in Scotland. They measured plasma Tn concentrations at presentation using a hsTnl assay and evaluated the negative predictive value of a range of hsTnl concentrations for the primary outcome of index MI, or subsequent MI or cardiac death at 30 days in derivation and validation cohorts. The median time from arrival in the ED to blood sampling for measurement of hsTn was 54 min. They found that a hsTn concentration of less than 5 ng/L at presentation met their pre-specified criteria for a negative predictive value of at least 99.5%. At this threshold, almost two-thirds of patients with suspected ACS could have been discharged with very few cardiac events. Indeed, implementation of this threshold could double the number of patients discharged directly from the ED.

In one study, Pickering et al.5 tested the 0–1 h rule out algorithm proposed by the current European Guidelines on 2015 ESC guidelines for the management of ACS in patients presenting without persistent ST-segment elevation, in 2222 patients with serial hsTnT and hsTnl measurements. The 0–1 h hsTnT algorithm ruled
et al.\textsuperscript{7} assessed the potential diagnostic role of circulating micro-RNAs in patients with ACS. They found that miR-221-3p was significantly positively correlated with Tn levels, GRACE and SYNTAX Score and inversely correlated with post-MI left ventricular systolic function. They conclude that miR-221-3p may be a promising biomarker for early diagnosing of ACS.

**Coronary computed tomography angiography**

It is uncertain whether a diagnostic strategy supplemented by early coronary computed tomography angiography (CCTA) is superior to contemporary standard optimal care including hsTn for patients suspected of ACS in the ED. In a prospective, open-label, mul-

---

**Figure 2.** In the CHAMPION PHOENIX trial, Guitierrez et al.\textsuperscript{13} analysed among 11 145 patients whether the femoral or radial approach for PCI interacted with the efficacy and safety of cangrelor. (A) Kaplan–Meier curves for the primary efficacy endpoint in the subgroup undergoing femoral access (cangrelor vs. clopidogrel). (B) Kaplan–Meier curves for the primary efficacy endpoint in the subgroup undergoing radial access (cangrelor vs. clopidogrel). HR, hazard ratio; CI, confidence interval. Reproduced with permission from Guitierrez et al.\textsuperscript{13}
ticentre, randomized trial, Dedic et al.\textsuperscript{8} enrolled 500 patients presenting with symptoms suggestive of an ACS at the ED of 5 community and 2 university hospitals in the Netherlands. The primary endpoint was the number of patients identified with significant coronary artery disease requiring revascularization within 30 days. There was no difference in the primary endpoint. Discharge from the ED was not more frequent after CCTA and length of stay was similar. The authors conclude that in the era of hsTnTs, CCTA does not identify more patients with significant CAD requiring coronary revascularization, neither does it shorten hospital stay, or allow for more direct discharge from the ED.

**RISK STRATIFICATION**

**Clinical scores**

McNamara et al.\textsuperscript{9} using the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry–GWTG (Get With the Guidelines) database developed a multivariate hierarchical logistic regression model predicting in-hospital mortality. The population (243,440 patients from 655 hospitals) was divided into a 60% sample for model derivation, with the remaining 40% used for model validation. A simplified risk score was created to enable prospective risk stratification in clinical care. Age, heart rate, systolic blood pressure, presentation after cardiac arrest, presentation in cardiogenic shock, presentation in heart failure, presentation with ST-segment elevation MI, creatinine clearance, and Tn ratio were all independently associated with in-hospital mortality. Observed mortality rates varied substantially across risk groups, ranging from 0.4% in the lowest risk group (score <30) to 49.5% in the highest risk group (score >59). This work built upon and extended prior mortality risk models developed for patients with AMI. Although valuable for the selected populations at the time of their original development, changes in patient profiles and AMI management demand updating. The new risk score might serve this purpose.

In a pooled cohort analysis which merged individual data from 48,286 participants in 4 trials Hess et al.\textsuperscript{10}
Biomarkers

Hagstrom et al.\textsuperscript{11} assessed independent associations between growth differentiation factor-15 (GDF-15) levels and major bleeding and CV events in patients with ACS patients randomized to ticagrelor or clopidogrel in the PLATO (PLATelet inhibition and patient Outcomes) trial. In Cox proportional hazards models adjusting for established risk factors for CV disease and prognostic biomarkers (N-terminal pro B-type natriuretic peptide, cystatin C, high-sensitive C-reactive protein, and hsTn), GDF-15 was associated with increased risk of major bleeding and of the composite of CV death, spontaneous MI, and stroke. The mechanism for the association between GDF-15 and the risk of bleeding might be related to an inhibitory effect on platelet activation mediated via a mechanism similar to glycoprotein IIb/IIIa inhibition resulting in a lower abil-

### Table

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>DCS N(%)</th>
<th>BMS N(%)</th>
<th>Hazard ratio (95% CI)</th>
<th>Interaction P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinically-driven TLR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>1 (1.85%)</td>
<td>2 (4.3%)</td>
<td>0.434 (0.039:4.79)</td>
<td>0.5495</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>11 (4.37%)</td>
<td>25 (9.76%)</td>
<td>0.42 (0.207:0.854)</td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>12 (3.92%)</td>
<td>27 (9.96%)</td>
<td>0.415 (0.210:0.82)</td>
<td></td>
</tr>
<tr>
<td>Non-ACS</td>
<td>47 (5.49%)</td>
<td>86 (10.14%)</td>
<td>0.528 (0.370:0.754)</td>
<td></td>
</tr>
<tr>
<td>Primary safety endpoint</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>4 (7.09%)</td>
<td>5 (10.72%)</td>
<td>0.646 (0.174:2.418)</td>
<td></td>
</tr>
<tr>
<td>NSTEMI</td>
<td>28 (6.08%)</td>
<td>54 (18.84%)</td>
<td>0.474 (0.267:0.757)</td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>30 (9.32%)</td>
<td>59 (18.51%)</td>
<td>0.485 (0.312:0.753)</td>
<td></td>
</tr>
<tr>
<td>Non-ACS</td>
<td>82 (8.37%)</td>
<td>95 (10.86%)</td>
<td>0.648 (0.632:1.141)</td>
<td></td>
</tr>
<tr>
<td>Cardiac death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>2 (3.51%)</td>
<td>0 (0%)</td>
<td>0.412 (0.19:0.895)</td>
<td>0.1223</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>9 (3.41%)</td>
<td>22 (6.12%)</td>
<td>0.491 (0.238:1.012)</td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>11 (3.42%)</td>
<td>22 (6.92%)</td>
<td>0.942 (0.608:1.481)</td>
<td></td>
</tr>
<tr>
<td>Non-ACS</td>
<td>39 (4.48%)</td>
<td>41 (4.71%)</td>
<td>0.924 (0.608:1.481)</td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>2 (3.71%)</td>
<td>5 (10.72%)</td>
<td>0.323 (0.063:1.688)</td>
<td>0.1215</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>20 (7.63%)</td>
<td>38 (14.4%)</td>
<td>0.518 (0.301:0.89)</td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>22 (6.95%)</td>
<td>43 (13.82%)</td>
<td>0.487 (0.291:0.814)</td>
<td></td>
</tr>
<tr>
<td>Non-ACS</td>
<td>50 (5.75%)</td>
<td>61 (7.07%)</td>
<td>0.807 (0.555:1.173)</td>
<td></td>
</tr>
<tr>
<td>Definite/Probable ST</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>1 (1.79%)</td>
<td>0 (0%)</td>
<td>0.301 (0.083:1.093)</td>
<td>0.0793</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>3 (1.13%)</td>
<td>10 (3.74%)</td>
<td>0.391 (0.123:1.246)</td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>4 (1.25%)</td>
<td>10 (3.18%)</td>
<td>1.241 (0.643:2.396)</td>
<td>0.528 (0.370:0.754)</td>
</tr>
</tbody>
</table>

Figure 4. In a randomized trial a Biolimus-A9 drug coated stent showed better outcomes with only 1-month dual antiplatelet therapy compared to a bare metal stent, in patients at high-bleeding risk. This sub-study focusing on patients with ACS was consistent with the overall findings. The benefit of the drug coated stent over the bare metal stent was consistent across various sub-groups, ACS, acute coronary syndrome; BMS, bare metal stent; DCS, drug coated stent; NSTEMI, non-ST-elevation myocardial infarction; ST, stent thrombosis; STEMI, ST-elevation myocardial infarction; TLR, target lesion revascularization. Reproduced with permission from Naber et al.\textsuperscript{22}.

---

found that sudden cardiac death (SCD) accounted for about one-third of CV deaths during 1-year follow-up and that reduced left ventricular ejection fraction, older age, diabetes mellitus, lower estimated glomerular filtration rate, higher heart rate, prior MI, peripheral artery disease, Asian race, male sex, and high Killip class were significantly associated with SCD. They also developed an integer-based score from this model, which yielded a calculated SCD probability ranging from 0.1 to 56.7%. This score might help in the identification of candidates for implantable cardioverter defibrillators above and beyond the mere assessment of ejection fraction although prospective assessment of device therapy is warranted because not all sudden death is arrhythmic and may in fact stem from other causes such as recurrent MI or cardiac rupture.
lity of the cells to form a thrombus. These findings give further support to the utilization of this biomarker in the clinical setting of ACS (Figure 1).

**TREATMENTS**

Mechanical reperfusion of the infarct-related artery by percutaneous coronary intervention (PCI) and adjunctive medical management including antithrombotic therapy remain the cornerstones of current ACS management.

**P2Y<sub>12</sub> inhibitors**

Recently the first intravenous P2Y<sub>12</sub> inhibitor, Cangrelor, was approved and broadened the armamentarium of antiplatelet agents in patients undergoing PCI. In the CHAMPION PHOENIX trial<sup>12</sup> Gutierrez et al.<sup>13</sup> analysed whether the femoral or radial approach for PCI interacted with the efficacy and safety of cangrelor. Among 11 145 patients randomly assigned to cangrelor or clopidogrel at the time of PCI the primary endpoint, a composite of death, MI, ischemia-driven revascularization, or stent thrombosis (Figure 2), occurred in the femoral cohort in 4.8% with cangrelor vs. 6.0% with clopidogrel (odds ratio, OR [95% confidence interval, CI]: 0.79 [0.65–0.96]); in the radial cohort, the primary endpoint was 4.4% with cangrelor vs. 5.7% with clopidogrel (OR [95% CI] 0.76 [0.54–1.06]). P for interaction was not significant. The absolute rate of bleedings tended to be lower with radial access.

The pharmacodynamics and pharmacokinetics of oral antiplatelet drugs, particularly P2Y<sub>12</sub> inhibitors may be affected by absorption and first pass metabolism. Furthermore, a drug–drug interaction between morphine and oral P2Y<sub>12</sub> receptor inhibitors, when administered together, has been suggested.<sup>14,15</sup> In a randomized double-blind trial, Kubica et al.<sup>16</sup> investigated the pharmacokinetics and pharmacodynamics of ticagrelor when administered with or without intravenous morphine in ACS patients. In 70 randomized patients, morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC (0–12): 6307 vs. 9791 ng h/mL; P=0.003), and 37%, respectively (AUC(0–12): 1503 vs. 2388 ng h/mL; P=0.008). Despite this impressive interaction, the clinical significance remains to be determined.

Concurrently, an analysis of 45 073 ACS patients from the SWEDEHEART registry<sup>17</sup> compared the outcomes of those treated with ticagrelor vs. those receiving clopidogrel. After 2 years, treatment with ticagrelor was associated with a lower rate of death (5.8% vs. 12.9%, adjusted hazard ratio [HR] 0.83 [0.75–0.92]) and a lower rate of MI (6.1 vs. 10.8%, adjusted HR 0.89 [0.78–1.01]) compared to clopidogrel (Figure 3). These real-world findings were consistent with previous randomized trial results.<sup>18</sup>

In STEMI patients undergoing primary PCI delayed antiplatelet effects of oral P2Y<sub>12</sub> inhibitors, including prasugrel, have been observed. Rollini et al.<sup>19</sup> investigated the bioavailability of crushed prasugrel tablets vs. whole prasugrel tablets. The study showed that compared with whole tablets, crushed prasugrel led to reduced P2Y<sub>12</sub> reaction units by 30 min post-loading dose, which persisted at 1, 2, and 4 h post-loading dose. Thus, in STEMI patients undergoing primary PCI, crushed prasugrel leads to faster drug absorption, and consequently, more prompt and potent antiplatelet effects compared with whole tablet ingestion. Whether this observation may be associated with clinical endpoints (e.g. acute stent thrombosis) needs to be determined in larger cohorts.

**Optimal dual antiplatelet treatment duration**

The optimal duration of DAPT after PCI in the setting of ACS is continuously debated as patients considered at high risk of bleeding may benefit from a shortened DAPT duration. In contrast, subsequent ischemic events in stable post ACS patients may be reduced by prolonged DAPT beyond 1 year, as was suggested in a meta-analysis.<sup>20</sup> However, major bleeding occurs significantly more often under prolonged DAPT.

In a randomized trial, a Biolimus-A9 drug coated stent (DCS) has shown better outcomes with only one month DAPT compared to a bare metal stent (BMS) in patients at high-bleeding risk.<sup>21</sup> A sub-study focusing on patients with ACS<sup>22</sup> was consistent with the overall findings. At 12-month follow-up, treatment with the DCS in ACS patients was more effective (clinically driven target-lesion revascularization 3.9% vs. 9.0%, P=0.009) and safer (cumulative incidence of cardiac death, MI, or definite or probable stent thrombosis 9.3% vs. 18.5%, P=0.001), than the BMS despite one month DAPT in both groups (Figure 4). As the DCS exhibited a better safety and efficacy profile than BMS, the use of BMS has to be questioned for the treatment of coronary artery stenosis. However, the lower cost of the BMS is a favourable argument in an environment with limited resources.

**Bivalirudin**

In primary PCI for ST-segment elevation MI (STEMI), theHORIZONS trial<sup>23</sup> had previously shown a mortality benefit for bivalirudin over heparin with glycoprotein inhibitors (GPI). Subsequent trials<sup>24–27</sup> comparing...
bivalirudin with other anti-thrombotic strategies rendered divergent results. Now a real-world analysis of 61,136 patients from the UK national PCI registry from 2008 to 2012 showed no significant difference in short- or medium-term mortality between STEMI patients treated with bivalirudin vs. heparin and GPI at primary PCI. Larger randomized trials will be needed to settle the role of bivalirudin vs. heparin in primary PCI.

**Beta-blockade**
The impact of intravenous beta-blockers before primary PCI on clinical outcomes and infarct size is not well established. A post hoc analysis from the METOCARD-CNIC trial suggested that the sooner metoprolol is administered in the course of an STEMI, the smaller the infarct size. However, the Early-BAMI trial did not show any difference between STEMI patients randomized to early intravenous metoprolol or placebo. In this study, metoprolol reduced the incidence of malignant arrhythmias in the acute phase but was not associated with a reduction in the infarct size (peak and area under the creatine kinase curve).

**Lipid lowering agents**
Pharmacotherapy that reduces low-density lipoprotein cholesterol has consistently shown benefit for CV endpoints in patients with coronary artery disease. In an analysis of the IMPROVE-IT trial, the addition of ezetimibe to simvastatin not only reduced the rate of first primary endpoint but also reduced the rate of subsequent adverse CV endpoints in ACS patients. Meanwhile a new class of agents—proprotein convertase subtilisin/kexin type 9 inhibitors, which are approved for the treatment of familiar hypercholesterolemia, are under investigation in ACS patients (ClinicalTrials.gov Identifier: NCT01663402).

**Fibrinolysis in non-PCI capable hospitals**
The preferred reperfusion strategy for ACS patients presenting with STEMI is primary PCI. However, systemic fibrinolysis is still applied in STEMI patients in non-PCI capable hospitals if transfer for primary PCI would lead to unacceptable reperfusion delays. In a prospective multicentre STEMI registry, Carrillo et al. compared the effect of in situ fibrinolysis vs. PCI transfer on 30-day mortality in a real-life consecutive cohort of 2470 STEMI patients. The study showed that patients in the transfer group whose from first medical contact (FMC) to device (PCI) time was achieved within 140 min were associated with significantly lower mortality (2.0% for FMC-device <99 min, and 4.6% for FMC-device 99–140 min; P=0.01 and P=0.03, respectively vs. fibrinolysis). Multivariable logistic regression analysis, reperfusion with fibrinolysis was an independent 30-day mortality predictive factor (OR: 1.91, 95% CI: 1.01–3.50; P=0.04). These results suggest, that transfer to a PCI-capable hospital should be recommended, if FMC-device delay is less than 140 min.

**Revascularization strategies in ACS**
A third to half of ACS patients present with multivessel disease. The best treatment strategy and the optimal timing for non-culprit lesion PCI in ACS is a matter of debate. In the SMILE trial, 584 patients with non ST elevation MI with multi-vessel disease were randomized to single-stage complete revascularisation vs. multi-stage complete revascularisation during the same hospitalization. No significant difference in the one-year incidence of cardiac death (3.41% vs. 5.32% respectively, P=0.27) and MI (2.65% vs. 3.8% respectively, P=0.46) was found between groups, although target vessel revascularisation was higher in the multistage group (8.33% vs. 15.2%, P=0.01). However, there was no overall survival benefit of single- vs. multistaged complete revascularisation.

If the culprit lesion of an ACS is located in an unprotected left main coronary artery (ULMCA), the optimal revascularization strategy is a matter of debate. In the DELTA all-comer, multinational registry the long-term outcomes of ACS patients with ULMCA treated with coronary artery bypass grafting (CABG) or PCI was investigated. In 379 ACS patients, no significant differences emerged for the composite endpoint of all-cause death, AMI, and cerebrovascular accident. As patients in this study received first-generation drug eluting stents a lower rate of target vessel revascularisation may be expected with newer-generation stents.

**Treatment of the elderly**
Schoenenberger et al. analysed the use of guideline-recommended therapies and in-hospital outcomes of 13,662 ACS patients ≥70 years enrolled in the prospective Acute Myocardial Infarction in Switzerland (AMIS) cohort according to 4-year periods (2001–2004, 2005–2008, and 2009–2012). Between first and last 4-year period, PCI use increased as well as use of guideline recommended drugs. At the same time, in-hospital mortality of the overall population decreased from 11.6% in the first to 10.0% in the last 4-year period, and in-hospital major adverse cardiac and cerebrovascular events from 14.4 to 11.3%. This study indicates that increasing use of guideline-recommended therapies is appropriate in the elderly. It remains to
establish whether this notion is also valid for octogenarians.

One aspect in the very elderly population was investigated by Tegn et al. They studied whether patients aged 80 years or older presenting with an ACS without ST-segment elevation would benefit from an early invasive strategy compared to an initially conservative management. During a median follow-up of 1.53 years, the primary outcome, a composite of MI, need for urgent revascularization, stroke, and death, occurred in 93 (40.6%) of 229 patients assigned to the invasive group and 140 (61.4%) of 228 patients assigned to the conservative group (HR 0.53 [95% CI 0.41–0.69], P = 0.0001). The two strategies did not differ in terms of bleeding complications. In conclusion, in line with the ESC Guidelines, an invasive strategy in patients aged 80 years or older presenting with non-ST segment elevation MI was superior to a conservative strategy.

**Left ventricular assist device**

Patients who present with acute heart failure or cardiogenic shock refractory to reperfusion and medication may require mechanical circulatory support. In the INTERMACS registry patients who received a durable ventricular assist device (VAD) in the setting of an ACS were compared to those who received a VAD for non-ACS indications. In an unadjusted analysis the ACS group had higher early phase hazard (HR: 1.24; P = 0.04) but reduced late-phase hazard of death (HR: 0.57; P = 0.04) than the non-ACS group. Despite being more critically ill before VAD implantation, ACS patients had similar outcomes compared to non-ACS patients. Therefore, VAD implantation is a valuable strategy in ACS patients with cardiogenic shock or heart failure refractory to medical therapy.

**OUTCOMES IN SPECIFIC PATIENT POPULATIONS**

**Women**

An interesting scientific statement from the American Heart Association on ACS in women summarizes the main differences between men and women in this setting. In particular, it is highlighted that regardless of age, within a year of a first AMI, more women than men die; within 5 years of a first AMI, more women than men die, have heart failure, or suffer from a stroke, although the higher mortality for women compared with men is explained partially by differences in risk factors, clinical presentation, and treatment. Indeed, the prevalence of diabetes mellitus, heart failure, hypertension, depression, and renal dysfunction is higher in women compared with men. Compared with men, women more commonly present with NSTEMI and nonobstructive coronary artery disease. Women are also more likely to have unusual pathophysiological mechanisms of ACS such as spontaneous coronary artery dissection or coronary artery spasm.

**Smokers**

Symons et al. assessed the effect of smoking in 471 STEMI patients by cardiac magnetic resonance. Smoking was associated with intramyocardial haemorrhage (IMH) at baseline even after correction for other factors associated with ischemia-reperfusion injury. Unexpectedly, smoking was an independent protective predictor against adverse left ventricular remodelling consistent with the ‘smoker’s paradox’, although the presence of IMH at baseline abolished this paradoxical, beneficial effects of smoking. It remains to establish what mediates these intriguing protective effects of smoking in STEMI in order to identify new therapeutic targets.

**Rheumatoid arthritis**

Despite a wealth of studies describing an increased incidence of ACS in rheumatoid arthritis (RA), considerably less is known about the clinical characteristics and their association with short-term outcome of such ACS. Mantel et al. compared the clinical presentation of incident ACS in a cohort of 1135 subjects with prevalent RA and in a cohort of 3184 matched general population comparators. RA subjects more frequently presented with SCD, STEMI, had higher levels of hsTn and higher frequencies of in-hospital complications compared with the general population comparators. Furthermore, the short-term mortality was higher among RA-associated ACS. The higher risk of RA-associated ACS is consistent with the important role of inflammation in the pathogenesis of ACS and should stimulate further research for the identification of personalized forms of treatment.

**Vasospastic angina**

Ahn et al. compared the outcomes of 188 patients with vasospastic angina and aborted SCD and 1844 patients with vasospastic angina without aborted SCD enrolled from 13 heart centres in South Korea. The former had a much higher risk of death than the latter. Predictors of SCD included age, hyperlipidaemia, family history of SCD, multi-vessel spasm, and left anterior descending artery spasm. It remains to establish which mechanisms make the myocardium more susceptible to malignant arrhythmias in these patients.
**Figure 5.** Typical angiographic presentation of ST-segment elevation myocardial infarction (STEMI), non-STEMI, Takotsubo syndrome, and Prinzmetal angina. Reproduced with permission from Luscher and Templin.43

**Figure 6.** Macrovascular and microvascular ischemia in patients with ST-segment elevation myocardial infarction (STEMI), non-STEMI, Takotsubo syndrome and Prinzmetal angina, respectively. Reproduced with permission from Luscher and Templin.43
Takotsubo syndrome
Finally, an emerging notion is that ACS are not only caused by epicardial anatomic or functional alterations but also by coronary microvascular dysfunction (Figure 5). This seems to be the case, in particular for takotsubo cardiomyopathy (TTC) (Figure 6). To this regards, one study illustrated that TTC can be triggered by not only negative but also positive life events. While patient characteristics and also short- and long-term outcomes were similar between groups, the midventricular TTC type was more prevalent among the ‘happy hearts’ than among the ‘broken hearts’. Presumably, despite their distinct nature, happy and sad life events may share similar final common emotional pathways, which can ultimately trigger TTC.

PERSPECTIVES
Major progress has been made in the understanding of ACS. In particular, novel data indicate that both basophils and eosinophils may play a pathogenetic role in ACS suggesting new potential therapeutic targets. Further efforts are also needed in the early diagnosis of ACS when it remains undetermined after optimal Tn assessment. The demonstration that GDF-15 predicts both ischemic and bleeding risk is exciting although its role in daily practice remains to be established. With regards to antithrombotic treatment, it remains challenging to tailor DAPT duration according to individual risk. Finally, the worse outcome of patients with RA as compared to those without RA indicates that the former need more aggressive forms of treatment to be defined in future studies.

Conflict of interest: F. Crea has received speaker fees from Astra Zeneca and Servier. R.K. Binder has received speakers fees from Astra Zeneca, is consultant for Biotronik and proctor for Boston Scientific. T.F. Lüscher has received institutional grants from Astra Zeneca, Eli Lilly, Medtronic, Boston Scientific and Biotronic as well as speaker fees from Astra Zeneca and Adjudication Committee fees from Bayer.

References
The year in cardiology 2016: acute coronary syndromes
Filippo Crea et al.


